Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2021 | Highlights from SABCS 2021

Charles Coombes • 8 Dec 2021
SABCS 2021
Breast Cancer Elacestrant
EMERALD

Charles Coombes, MD, PhD, Imperial College London, London, UK, highlights key learnings from this years San Antonio Breast Cancer Symposium 2021, including the findings from EMERALD (NCT03778931), a Phase III study evaluating elacestrant vs standard of care in patients with HR+/HER2- breast cancer. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

More from Charles Coombes

5:02
Samuraciclib in combination with fulvestrant in patients with advanced HR+/HER2- breast cancer
Charles Coombes • 8 Dec 2021
2:53
REACT: effect of celecoxib vs placebo as adjuvant therapy on DFS among patients with breast cancer
Charles Coombes • 8 Dec 2021

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals